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Consumers are becoming more aware of functional foods and
supplements and the potential role of these products in a
balanced diet and in ensuring good health.1 Functional foods
are defined as foods that contain physiologically active
components, which provide health benefits beyond basic
nutrition2 by affecting one or more functions in the body in a
targeted way.3 ‘The functional component could include an
essential macronutrient with specific physiological effects such
as an essential micronutrient’3, ‘components that have some
nutritive value but are not classified as “essential“, such as
oligosaccharides, or food components with no nutritive value,
such as live microorganisms or plant chemicals’.3 ‘A dietary
supplement is defined as a product intended for ingestion as a
supplement to the diet’.4 Supplements may contain one or
more of the following ingredients: vitamins, minerals, herbs,
botanicals, or other plant-derived substances; amino acids,
enzymes, concentrates and extracts.  Dietary supplements can
be manufactured as pills, tablets, capsules, gelcaps, liquids and
powders.4
In many countries the functional food market seems to be
dominated by gut health products, in particular probiotic- and
prebiotic-containing products.5 Fuller6 defines a probiotic as ‘a
live microbial food supplement that beneficially affects the host
animal by improving its intestinal microbial balance’.
Probiotics are available in the form of various pharmaceutical
preparations, e.g.  powders, liquid suspensions and tablets, or
are incorporated in, for example, fermented food products to
produce functional foods.6, 7
The latest trend in the functional food market is to combine
probiotics with prebiotics to enhance the effect of probiotics.5
Prebiotics are defined as ‘non-digestible food ingredients that
beneficially affect the host by selectively stimulating the
growth and/or activity of probiotic bacteria in the colon’.8
However, prebiotics also have health benefits that are not
related to the simultaneous intake of probiotics.  Inulin and
fructo-oligosaccharides are among the most common prebiotics
included in breakfast cereals and nutritional drinks or used in
combination with probiotics in nutritional supplements.9
Because of the presence of potentially pathogenic species
such as Enterococcus faecium and E. faecalis in probiotic
products,1,10 the production and marketing of functional foods
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numbers in the proposed South African regulations.
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should be strictly controlled and carefully monitored.11
Information on the label of the product, especially regarding
the composition and identity of the probiotic strains included,
needs to be accurate to guarantee safety and functionality.12
Recent studies conducted on probiotic supplements and dairy
products in Europe and  South Africa revealed possible
irregularities in this regard.  In most cases the identity and
number of viable strains recovered did not correspond with the
information on the label.12-14
One solution in addressing the problems mentioned with
product content involves relevant and effective legislation.
However, despite the large market segment occupied by
probiotic foods and supplements in Europe, no specific
regulations regarding the labelling of these products exist in
that region.15 On the other hand, although this particular
market has not yet been that well developed in the USA, the
United States Food and Drug Administration (FDA) strictly
regulates the labelling and marketing of conventional foods
containing probiotic bacteria.  In South Africa permissible
statements regarding the health benefits of probiotic and
prebiotic claims are included in the proposed regulations
governing labelling and advertising in the Foodstuffs,
Cosmetics and Disinfectants Act, 1972 (Act No. 54 of 1972
(referred to as ‘proposed South African regulations’ from here
onwards), www.doh.gov.za).  However, despite the fact that
these regulations are being finalised, limited information is
available regarding the probiotic- and prebiotic-containing
product market in South Africa.
In view of the above, the aims of this study were to complete
a market and product assessment of probiotic- and prebiotic-
containing products manufactured in South Africa.  This
involved identifying the range of products available on the
South African market and evaluating claims made on the
labels.
Materials and methods
Identification of probiotic and prebiotic products on
the South African market
For the purposes of this study ‘probiotic- and prebiotic-
containing products manufactured in South Africa’ are defined
as all products manufactured in South Africa that contain
probiotics and/or prebiotics.  For the identification of such
products available on the South African market during the
period 1 February - 1 September 2003, the following
information sources were scrutinised or visited: general
grocery outlets, health food stores, websites, published
information including scientific literature, advertisements and
pamphlets.  Every identified product was listed and the
following information was recorded: type of product (tablet,
syrup or powdered form), specific target group (if applicable),
probiotic strains (strain, number of viable cells (colony forming
units (cfu)/g) and prebiotic (type and concentration).
Evaluation of claims on probiotic- and prebiotic-
containing products manufactured in South Africa
For the purposes of this study ‘claims’ are defined as: (i)
health-related claims, e.g. ‘treatment and prevention of
diarrhoea’; and (ii) probiotic and prebiotic content-related
claims, i.e. strain and viable cell numbers of probiotics and
concentration of prebiotics included.
Evaluation of health-related claims based on proposed South
African regulations
The health-related claims regarding probiotics and prebiotics
on each identified product were listed and similar claims were
grouped together.  To determine whether it complied with the
regulations or not, the wording/content of each of the claims
was subsequently compared with the prescribed wording/
content claim as proposed by the South African regulations.
Evaluation of health claims based on scientific soundness
The scientific soundness of each of the identified claims was
assessed by searching the scientific literature for any published
study providing data in support of the claim.  In this process it
was assumed that the publication of a paper in a scientific
journal is not necessarily final proof of the scientific soundness
of such a claim.  To address this issue, the quality of each
identified paper was assessed based on the study design
applied.  According to Farnworth,16 it is generally accepted that
health claims concerning specific nutrients/foods/functional
components need to be assessed using a randomised controlled
trial (RCT).  The following criteria of RCTs in humans4 were
therefore used to assess the quality of the identified papers: 
(i) the measurements used must be objective — subjective
claims, referred to as anecdotal evidence, which include
individual testimonials or opinions, are not acceptable objec-
tive measurements; (ii) the experimental population must be
appropriate, i.e. human, and the subjects used must be 
in line with those for whom conclusions were drawn and
recommendations formulated — for example, it is not
acceptable to use adult subjects and formulate health claims 
for children; (iii) the study must include a control group; (iv)
the study must include an experimental group; (v) subjects
must be randomly assigned to an experimental and control
group; (vi) control subjects must receive a placebo; (vii) the
study must be at least single-blinded, but preferably double-
blinded; and (viii) the journal in which the study was
published must be peer reviewed.
Although sample size is a very important factor to consider
in a study design, it was not possible to specify a minimum
sample size for a scientifically sound study for the assessment
of probiotic- and prebiotic-related health claims.  A criterion in
this regard was therefore not formulated.
A study was classified as scientifically sound if at least 7 out
of 8 of the mentioned criteria were met.  If any 2 or more of the
criteria were not met, the study was classified as lacking in
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scientific soundness, although not necessarily completely
worthless.  Although in vitro studies supply important
evidence regarding microbial activity and potential health
benefits, the final proof lies in the execution of well-planned
RCTs.  In vitro studies were therefore not accepted as a
scientific basis for the formulation of a health claim.
Evaluation of content claims regarding strains included,
viable cell numbers and prebiotic type and concentration
based on the proposed South African regulations
The probiotic strains and viable cell numbers, and prebiotic
type and concentration were listed for each identified product
and compared with the proposed South African regulations in
this regard.
Microbial assessment of viable cell numbers included in 5
selected probiotic supplements
Five probiotic supplements readily available in pharmacies
were selected to determine the viability (growth and inhibitory
activity) of the probiotic strains and to compare the actual
viable cell numbers with the ‘label’ claim in this regard.
The content of the capsule was resuspended in 10 ml sterile
distilled water, serially diluted and plated out, in duplicate,
onto a De Man Rogosa Sharpe (MRS) agar (Biolab, Diagnostics,
Midrand, South Africa).  Plates from each dilution were
incubated aerobically and anaerobically at 37°C and colonies
were counted after 24 hours.
To assess the viability of the probiotics included in the
products, probiotic strains isolated from each of the 5 products
were screened for inhibitory activity against the following 10
indicator strains isolated from the faeces of patients diagnosed
with AIDS: Salmonella typhi, S. typhimurium, Salmonella Gr.B.,
Shigella flexneri 1, S. flexneri 3, S. sonnei, S. boydii, Shigella spp.,
Yersinia spp. and Vibrio parahaemolyticus.  The probiotic strains
were cultured in MRS broth (Biolab) for 18 hours at 37°C and
10 µl was spotted on MRS agar (Biolab).  The plates were
incubated for 24 hours at 37°C and then lawned with active
cells of the indicator strains (approximately 106 cfu/ml),
embedded in soft agar (0.8%, m/v).  The plates were incubated
at 37°C for 24 hours and the colonies examined for the
formation of zones, which indicates the level of inhibitory
activity and therefore viability.  The study was done in
triplicate and the average determined.
Results 
The identified range of probiotic- and prebiotic-containing
products manufactured in South Africa includes 3 fortified
infant foods, 7 yoghurt products selected from a variety of
dairy products containing live cultures targeted at children and
adults, and 16 probiotic supplements of which 3 are targeted at
infants/children and 13 at adults.  A combination of probiotics
and prebiotics was found in 6 supplements, of which only 1 is
targeted at children, 2 energy drinks and 1 dairy product
targeted at children and adults.  Sixteen food items naturally
containing or fortified with prebiotics, including 2 supple-
ments, 2 breakfast cereals, 11 nutritional drinks and 1 muesli
bar, were identified.  Four of these are targeted at infants/
children, 4 at children and adults, and 8 at adults only.
Comparison of the health claims stated on the label of
probiotic- and prebiotic-containing products manufactured in
South Africa with the proposed South African regulations is
presented in Table I.  Scientific publications that seem to
support a particular claim are listed in the table.
These data indicate that only 3 of the 26 claims on the
identified products comply with the proposed South African
regulations, but that sound scientific evidence seems to be
available for all 3 of these claims.  It is of importance to note
that sound scientific evidence is also available for at least 5
claims not included in the proposed South African regulations,
including diarrhoea prevention in infants, diarrhoea prevention
in adults, improvement of digestive health and stool quality
and prevention of constipation, treatment of irritable bowel
syndrome, and treatment of food allergies.  Furthermore, no
sound scientific evidence could be traced for 16 of the 26 claims
that appeared on the identified products.
Probiotic strain claims made on the labels of identified
products all comply with the proposed South African
regulations with the exception of 4 dairy products and 1
supplement.  The claims concerning the included viable cell
numbers varied between 1 x108 cfu/g and 6 x109 cfu/g, which
is in line with the proposed South African regulations.  The
prebiotic type claims made on the labels of the identified
products include fructo-oligosaccharides, raftilose and chicory,
which are all permissible according to the proposed South
African regulations.  The labels of 3 products did not specify
the type of prebiotic but only claimed prebiotic fibre content,
which is not in line with the proposed South African
regulations.  The prebiotic concentration claims varied between
3 g and 15 g per 100 g, which is in line with the proposed
South African regulations.
Comparison of viable cell numbers stated on the labels of the
supplements with the actual viable cell numbers is presented in
Table II. Based on these results, the viable cell numbers in
supplements 1 and 5 are in line with the viable cell numbers as
stated on the labels.  The viable cell numbers in supplement 2
were 2 log-cycles lower, and in supplements 3 and 4, 1 log-
cycle lower than the claimed number.  The actual viable cell
numbers in supplement 4 do not comply with the proposed
South African regulations.
The results of the screening of the probiotic strains isolated
from the 5 selected supplements against a panel of 10 indicator
strains are presented in Table III. It is evident that all strains
showed good inhibitory activity against the panel of indicator
strains isolated from faeces of patients diagnosed with AIDS, as
is indicated by the diameter recorded for each of the inhibition
zones.
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Discussion
The probiotic- and prebiotic-containing product market is a
fast-growing industry worldwide and the list of available 
products increases on a daily basis.39 In the USA, Europe and
Japan the probiotic and prebiotic market seems to be
dominated by dairy products, including yoghurt and
fermented drinks.40,41 Although not an exhaustive list, a large
Table I. Claims stated on the labels of probiotic- and/or prebiotic-containing products, publications supporting claims and
compliance with the proposed South African regulations
Complies with SA
Claims References complied with 7/8 criteria regulations
Prevention of diarrhoea in infants Kaila et al.,17 Saavedra et al.,18 Shornikova No 
et al.,19 Guandalini et al.,20 Haschke et al.,21
Hatakka et al.22 Szajewska and Mrukowicz23
Assists in prevention and treatment of None No
nappy rash
Assists in prevention and treatment None No
of constipation
Assists in protection of infants in None No
hygienically compromised situations
Decreases symptoms of lactose intolerance Vesa et al.24 Yes
Treatment of colon disorders None No
Replenishes intestinal flora of adults Sittonen et al.,25 Orrhage et al.,26 Cremonini et al.27 Yes
(after antibiotic treatment)
Helps the body to alleviate diarrhoea Sittonen et al.,25 Orrhage et al.,26 Cremonini et al.27 No
naturally in adults
Improves digestive health, improves Saavedra et al.,28 Haschke et al.21 No
stool quality, prevents constipation
Helps the body to alleviate None No
flatulence naturally
Reverses the negative effects of None No
antibiotics on the digestive tract
Reverses the negative effects of None No
alcohol on the digestive tract 
Reverses the negative effects of None No
stress on the digestive tract 
Reverses the negative effects of None No
poor diet on the digestive tract
Inhibits intestinal and food None No
poisoning pathogens including 
Escherichia coli, Streptococci and 
Salmonella and feeds friendly 
bacteria, balances intestinal pH
Assists in promotion of healthy None No
bowel flora for treatment of acidity, 
heartburn, indigestion and digestive upsets
Very effective in treating irritable Pelto et al.,29 Gionchetti et al.,30 Niedzielin et al.31 No
bowel syndrome/colitis/ 
radiation-caused enterocolitis
Very effective in treating Crohn’s disease Pelto et al.29 No
Very effective in preventing dyspepsia None No
Restores and maintains the normal None No
vaginal flora (mainly lactic acid bacteria) 
frequently destroyed by the administration 
of broad-spectrum antibiotics and the use 
of disinfectants, soaps and deodorants
Treatment of food allergies Heyman et al.,32 Majamaa et al.,33 Isolauri et al.34 No
Treatment of acne None No
Boosts immune system Link-Amster et al.,35 Schiffrin et al.,36 Mattila- Yes
Sandholm and Kauppila,1 Fisberg et al.,37 Haschke et al..21
Treatment during steroid therapy None No
Treatment during chemotherapy None No
Treatment during radiotherapy Hendriksson et al.38 No
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variety of probiotic- and prebiotic-containing products
manufactured in South Africa were identified in this study.
The range of products on the South African market includes
probiotic and prebiotic supplements (capsules) and fortified
food items, fermented foods containing probiotics, e.g. dairy
products, and probiotics used in combination with prebiotics in
supplements and food fortification.  Dairy products seem 
to be prominent in the market, although fortified cereals,
especially baby cereals, and supplements also seem to be
growing markets.
It is important that the health claims stated on the labels of
products supply the consumer with reliable information
because such claims influence consumer behaviour and
potentially affect public health.42 From this research it was
evident that quite a number of claims stated on the labels of
products cannot be substantiated by scientific evidence and are
therefore misleading.  Besides the fact that the consumer is
being manipulated into buying a product under false
pretences, it could potentially be dangerous if such products
are used to treat a condition instead of the individual seeking
medical help.43 Manufacturers and marketers of these products
should therefore be held accountable for health-related claims
on products via appropriate legislation.
Unlike the European situation,40 South African legislators
have formulated proposed regulations for labelling of
probiotic- and/or prebiotic-containing products in the
Foodstuffs, Cosmetics and Disinfectants Act (Act No. 54 of
1972, www.doh.gov.za). Only 3 of 26 claims complied with
proposed South African regulations.  Sound scientific evidence
was found for 5 additional claims not included in these
regulations.  Because of incomplete information on labels, the
consumer is misinformed.  We propose a revision of the South
African regulations to include the following 5 claims: diarrhoea
prevention in infants, diarrhoea prevention in adults,
improvement of digestive health and stool quality and
prevention of constipation, treatment of irritable bowel
syndrome, and treatment of food allergies.
The probiotic and prebiotic content-related claims (strain,
viable cell number, type of probiotic and prebiotic concen-
tration) on the labels were mostly in line with the proposed
South African regulations.  Probiotic cultures most commonly
claimed on the labels of supplements and functional foods
include Lactobacillus acidophilus, Bificobacterium bifidum and 
B. longum, which are the same species generally claimed to be
included in European probiotic supplements.12 It is of concern
that quite a number of products on the South African market
only claim L. acidophilus and Bifidobacterium sp. (AB-culture)
content or prebiotic fibre content without specifying probiotic
species, viable cell numbers, prebiotic type and concentration.
This situation indicates that the proposed South African
Table II. Comparison of the actual viable cell numbers with the claims on the labels of 5 probiotic supplements manufactured
in South Africa
Viable cell numbers stated on the Actual viable cell numbers identified
Supplement label of the supplement (cfu/g) (aerobic/anaerobic (cfu/g))
1 1 × 108 1 × 108/1.7 × 108
2 1 × 108 2.8 × 106/3 × 106
3* 1 × 108 2 × 107
4 1 × 108 4 × 105/1.4 × 107
5* 1 × 107 1.5 × 107
*Supplements 3 and 5 contained no bifidobacteria and cell counts were not determined from anaerobically incubated plates.
Table III. Inhibitory activity of probiotic strains from 5 probiotic supplements manufactured in South Africa against a panel
of indicator strains
Supplement Supplement Supplement Supplement Supplement
1 2 3 4 5
Human pathogens Zone size (mm)
Salmonella typhi 26 - 30 26 - 30 26 - 30 26 - 30 26 - 30
Yersinia spp. 26 - 30 20 - 25 26 - 30 20 - 25 20 - 25
Shigella flexneri 1 31 - 35 26 - 30 26 - 30 20 - 25 26 - 30
Salmonella typhimurium 31 - 35 31 - 35 20 - 25 26 - 30 20 - 25
Shigella flexneri 3 31 - 35 31 - 35 26 - 30 20 - 25 31 - 35
Shigella sonnei 26 - 30 ≥ 36 26 - 30 26 - 30 ≥ 36
Shigella boydii ≥ 36 ≥ 36 26 - 30 31 - 35 ≥ 36
Salmonella Gr. B 26 - 30 31 - 35 31 - 35 26 - 30 31 - 35
Shigella spp. ≥ 36 31 - 35 31 - 35 26 - 30 ≥ 36
Vibrio parahaemolyticus 31 - 35 26 - 30 26 - 30 26 - 30 31 - 35
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regulations are not being enforced and that it is not possible for
the consumer to make a well-informed decision on the use of
these products.  It is vitally important to rectify this.
Despite the fact that product label claims regarding viable
cell numbers are in line with the proposed South African
regulations, the same is not always true for the actual viable
cell numbers in products, as seen for 3 of the 5 probiotic
supplements tested.  This phenomenon is not uncommon as
Hamilton-Miller et al.,13 Temmerman et al.12 and Elliot and
Treversham14 also reported that the identity and number of
viable strains recovered from probiotic supplements and dairy
products in the UK, Europe and South Africa did not
correspond with the information on the label in many
instances.  Hamilton-Miller and Shah44 suggested that
manufacturers should ensure careful manufacturing practices
and proper storage of probiotic-containing products to ensure
cell survival. All the probiotic strains tested in this study
showed good inhibitory activity against the indicator strains.
These results might indicate that lower viable cell numbers
could be effective and therefore in vivo assessments should be
considered.
Conclusions and recommendations
A large variety of probiotic- and prebiotic-containing products
are available on the South African market.  Marketers of these
products are misleading consumers with a number of health
claims that are not scientifically sound and that do not comply
with legislation. The proposed South African regulations
should be revised.  The content-related claims on the labels
mostly comply with the proposed South African regulations,
although a number of products do not provide this
information.  It is also evident that the number of viable cells
listed on labels is not always correct.  The fact that this problem
does not seem to affect the inhibitory activity of the probiotic
strains might point to the need to implement in vivo
assessments.  If this finding is validated, a wider range of
prescribed viable cell numbers in the proposed South African
regulations should be considered.  We recommend that the
proposed South African regulations be revised regularly to
accommodate the results of ongoing scientific research in the
field of probiotics and prebiotics.
This study was funded by the Medical Research Council (MRC)
and National Research Foundation (NRF).
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